Pharmacogenetics of type 2 diabetes mellitus, the route toward tailored medicine

GC Mannino, F Andreozzi… - … /metabolism research and …, 2019 - Wiley Online Library
Type 2 diabetes mellitus (T2DM) is a chronic disease that has reached the levels of a global
epidemic. In order to achieve optimal glucose control, it is often necessary to rely on …

Personalized medicine in diabetes mellitus: current opportunities and future prospects

JW Kleinberger, TI Pollin - Annals of the New York Academy of …, 2015 - Wiley Online Library
Diabetes mellitus affects approximately 382 million individuals worldwide and is a leading
cause of morbidity and mortality. Over 40 and nearly 80 genetic loci influencing susceptibility …

Pharmacogenomics and personalized medicine in type 2 diabetes mellitus: potential implications for clinical practice

P Venkatachalapathy, S Padhilahouse… - Pharmacogenomics …, 2021 - Taylor & Francis
Type 2 diabetes mellitus (T2DM) is the most common form of diabetes, and is rising in
incidence with widespread prevalence. Multiple gene variants are associated with glucose …

Pharmacogenomics and pharmacogenetics of thiazolidinediones: role in diabetes and cardiovascular risk factors

D Della-Morte, R Palmirotta, AK Rehni… - …, 2014 - Taylor & Francis
The most important goal in the treatment of patients with diabetes is to prevent the risk of
cardiovascular disease (CVD), the first cause of mortality in these subjects …

Diabetes-related neurological implications and pharmacogenomics

CA Rojas-Carranza, RH Bustos-Cruz… - Current …, 2018 - ingentaconnect.com
Diabetes mellitus (DM) is the most commonly occurring cause of neuropathy around the
world and is beginning to grow in countries where there is a risk of obesity. DM Type …

Pharmacogenetics and personalized treatment of type 2 diabetes

S Semiz, T Dujic, A Causevic - Biochemia medica, 2013 - hrcak.srce.hr
Sažetak Type 2 diabetes mellitus (T2DM) is a worldwide epidemic with considerable health
and economic consequences. T2DM patients are often treated with more than one drug …

A systematic review of polygenic models for predicting drug outcomes

A Siemens, SJ Anderson, SR Rassekh… - Journal of Personalized …, 2022 - mdpi.com
Polygenic models have emerged as promising prediction tools for the prediction of complex
traits. Currently, the majority of polygenic models are developed in the context of predicting …

Does Thiazolidinedione therapy exacerbate fluid retention in congestive heart failure?

I Goltsman, EE Khoury, J Winaver, Z Abassi - Pharmacology & Therapeutics, 2016 - Elsevier
The ever-growing global burden of congestive heart failure (CHF) and type 2 diabetes
mellitus (T2DM) as well as their co-existence necessitate that anti-diabetic pharmacotherapy …

Personalized medicine in type 2 diabetes

WL Liao, FJ Tsai - BioMedicine, 2014 - Springer
Abstract Type 2 diabetes (T2D) is a global public health concern, its prevalence in Asia,
especially Taiwan, rising every year. The risk of developing T2D and diabetes complications …

The importance of precision medicine in type 2 diabetes mellitus (T2DM): from pharmacogenetic and pharmacoepigenetic aspects

F Khatami, MR Mohajeri-Tehrani… - … , Metabolic & Immune …, 2019 - ingentaconnect.com
Background: Type 2 Diabetes Mellitus (T2DM) is a worldwide disorder as the most important
challenges of health-care systems. Controlling the normal glycaemia greatly profit long-term …